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Abstract
 
Multiple sclerosis (MS) is a disabling inflammatory demyelinating disease of the central nervous
system, considered to result from self-reactivity to myelin antigens. Tumor necrosis factor
(TNF) and the p55 TNF receptor (TNFR) have been strongly implicated in MS pathogenesis.
We reveal in this study a dual role for TNF in experimental autoimmune encephalomyelitis
(EAE), a mouse model for MS. In addition to its well-established proinflammatory effects, TNF
exhibits potent immunosuppressive properties, providing one possible explanation for the im-
mune and disease activating effect of anti-TNF treatment of MS. We show that in TNF-defi-
cient mice, myelin-specific T cell reactivity fails to regress and expansion of activated/memory
T cells is abnormally prolonged, leading to exacerbated EAE. Strikingly, immnosuppression by
TNF and protection against EAE does not require the p55 TNFR, whereas the same receptor is
necessary for the detrimental effects of TNF during the acute phase of the disease. Thus, block-
ing the function of the p55 TNFR in autoimmune demyelination may inhibit the noxious
proinflammatory activities of TNF without compromising its immunosuppressive properties.
Key words: autoimmunity • cytokines • encephalomyelitis/multiple sclerosis • T lymphocytes • 
transgenic/knockout
 
Introduction
 
Multiple sclerosis (MS)
 
1
 
 is a chronic relapsing inflamma-
tory demyelinating disease of the central nervous system
(CNS), generally considered to result from aberrant T cell
reactivity to myelin antigens (1). No definite treatment for
MS yet exists and the role of certain suspected mediators in
animal models is often contradictory to what is seen when
tried experimentally in MS (2). A possible flaw in attempts
to rationalize therapeutic interventions in MS, based on
the activity of target molecules in animal models, may stem
 
from the fact that many such animal models, including
experimental autoimmune encephalomyelitis (EAE), are
often used to reproduce the acute phase of the disease,
providing a partial representation of the chronicity of
pathogenic mechanisms operating in MS (2). This be-
comes crucially important especially when target molecules
show context-dependent, pleiotropic, and often contrast-
ing biological activities. One such molecule is TNF, an es-
tablished mediator of inflammation, but also a molecule
implicated in the suppression or the termination of T cell
responses (3, 4).
An interesting feature discovered recently for both MS
and EAE is that primary myelin reactivity associated with
onset of disease invariably regresses with time and becomes
undetectable during consequent phases of the disease (5). In
contrast, secondary self-reactivity to spreading determinants
is consistently associated with disease progression (5, 6). Al-
though the physiological significance of spontaneous re-
gression of myelin reactivity remains unclear, it is likely
that this functional property of the immune system serves
to protect against potential autoimmune complications af-
ter exposure to self-antigens. Conversely, delay or failure to
suppress self-reactivity may lead to self-aggressiveness and
target tissue damage. Understanding the molecular details
of this important process is eagerly awaited.
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TNF has been suggested as an important mediator of MS
pathogenesis (7) and its detrimental role has been strongly
supported in several animal models for MS (8–11). Surpris-
ingly, however, systemic blockade of TNF in progressive
MS patients led to immune activation and increased disease
activity (12, 13). Although an antiinflammatory effect of
TNF in the initiation of EAE has been described (14), it has
not been associated with excessive myelin-directed T cell
reactivity. Furthermore, the bulk of evidence (including
this study) suggests that TNF/p55 TNFR signaling, in at
least the initiation phase of EAE, is detrimental rather than
antiinflammatory (8, 9, 15), and in all cases examined, pri-
mary T cell responses in TNF
 
2
 
/
 
2
 
 mice have been compara-
ble to those in control wild-type mice for up to 5 wk after
immunization (8, 9, 14). Therefore, although TNF shows a
clear proinflammatory activity in EAE and MS, it has re-
mained uncertain whether this molecule may also be in-
volved in the regulation of myelin-directed autoimmunity.
In an attempt to reconcile the pathogenic and immuno-
suppressive properties of TNF in autoimmune demyelina-
tion, we examined the long-term effects of TNF deficiency
on the induction and regression of a myelin-specific T cell
response. We show here that in the absence of TNF, my-
elin-specific T cell reactivity fails to regress and expansion
of activated/memory T cells is abnormally prolonged. Sur-
prisingly, failure to control myelin-specific autoimmunity
in TNF-deficient mice results in the exacerbation of au-
toimmune demyelination in both resistant and susceptible
backgrounds. Our results suggest that TNF deficiency pro-
longs and intensifies pathogenic autoimmunity, providing
one possible explanation for the immune activating effect of
anti-TNF treatment of MS. Intriguingly, immunosuppres-
sion by TNF and protection from chronic demyelinating
disease occurs independent of the presence of the p55
TNFR. Thus, uncoupling of the proinflammatory from the
immunosuppressive properties of TNF at the p55 TNFR
level becomes crucially important for immune modulation.
By specifically blocking the function of the p55 TNFR in
autoimmune demyelination, it may be possible to inhibit
the detrimental proinflammatory contributions of TNF
without compromising its immunosuppressive properties.
 
Materials and Methods
 
Mice.
 
TNF
 
2
 
/
 
2
 
 mice, generated in-house (16), and control
animals were maintained in a random C57BL/6 
 
3
 
 129/Sv (H-2
 
b
 
)
genetic background (referred to as B6,129). Mice originated from
C57BL/6 
 
3 
 
129/Sv F
 
2
 
 littermates, homozygous for the wild-type
or the mutant TNF allele, and were subsequently kept as indi-
vidual lines. Additionally, TNF
 
2
 
/
 
2
 
 mice were backcrossed to
C57BL/6 mice for at least six generations (referred to as inbred
B6.TNF
 
2
 
/
 
2
 
). B6,129.p55
 
2
 
/
 
2
 
 mice (17) were provided by Dr. H.
Bluethmann (F. Hoffmann-La Roche Ltd., Basel, Switzerland).
Inbred B6.p55
 
2
 
/
 
2
 
 mice (18) were obtained from The Jackson
Laboratory. B6,129.p55p75
 
2
 
/
 
2
 
 mice were generated by crossing
B6,129.p55
 
2
 
/
 
2
 
 mice with B6.p75
 
2
 
/
 
2
 
 mice (19), provided from
Dr. M.W. Moore (Genentech, Inc., South San Francisco, CA).
Specifically for myelin oligodendrocyte glycoprotein (MOG)-
induced EAE (see Fig. 4 b), B6,129.p55p75
 
2
 
/
 
2
 
 mice and B6,129
 
F
 
2
 
 control mice were obtained from The Jackson Laboratory. All
mice were maintained under specific pathogen-free conditions.
 
Immunizations.
 
Antigens were emulsified in CFA (Sigma-
Aldrich) containing 1 mg/ml 
 
Mycobacterium tuberculosis 
 
H37Ra. T
cell priming was assayed in popliteal LNs isolated from mice (7–
11 wk of age) 9 d after footpad immunization with 30 
 
m
 
g bovine
myelin basic protein (MBP; Sigma-Aldrich) in CFA containing a
total of 50 
 
m
 
g H37Ra per mouse. T cell “memory” was assayed
in the spleen of mice at indicated time points after tail-base im-
munization with 30 
 
m
 
g MBP or 50 
 
m
 
g OVA (Sigma-Aldrich) in
CFA containing a total of 100 
 
m
 
g H37Ra per mouse. Alterna-
tively, T cell “memory” was examined in popliteal LNs 5 d after
secondary footpad immunization with 30 
 
m
 
g MBP in IFA, 11–15
wk after the primary tail-base immunization.
 
T Cell Proliferation Assay.
 
T cell proliferative responses were
assessed at indicated time points in total LN or spleen cells. After
erythrocyte lysis, cells were cultured in flat-bottomed 96-well
plates at a density of 7 
 
3
 
 10
 
5
 
 per well. Culture medium consisted
of DMEM (Seromed) supplemented with 5% FCS, 
 
l
 
-glutamine,
and antibiotics. Triplicate cultures were incubated at 37
 
8
 
C in the
presence or in the absence of indicated concentrations of the an-
tigens. After 52 h, cultures were pulsed with 1 
 
m
 
Ci of [methyl-
 
3
 
H]TdR (Amersham Pharmacia Biotech) for 18 h. Cells were
then harvested on glass fiber filters and incorporation of [methyl-
 
3
 
H]TdR was measured by liquid scintillation counting. Results
are expressed as stimulation indices (cpm of antigen-stimulated
cultures/cpm of culture with medium alone).
 
Induction and Evaluation of EAE.
 
EAE was induced in female
B6.TNF
 
2
 
/
 
2
 
, B6.p55
 
2
 
/
 
2
 
, and control C57BL/6 mice or
B6,129p55p75
 
2
 
/
 
2
 
 and B6,129 F
 
2
 
 mice after immunization with a
rat MOG peptide (MOGp35–55, MEVGWYRSPFSRVVH-
LYRNGK; Sigma-Aldrich). Mice received in the two flanks 150
 
m
 
g MOGp35–55 emulsified with a total of 1 mg H37Ra (Difco
Laboratories) per mouse. Indicated doses of pertussis toxin (PTx;
Sigma-Aldrich) were injected intraperitoneally at the time of im-
munization and 48 h later. Mice were monitored regularly for
clinical signs and were scored on a scale of 0–5: 0, no clinical dis-
ease; 1, tail paralysis; 2, paraparesis (incomplete paralysis of one or
two hindlimbs); 3, paraplegia (complete paralysis of one or two
hindlimbs); 4, paraplegia with forelimb weakness or paralysis; and
5, moribund or dead animals. For histological evidence of EAE,
brains and spinal cords were removed, immersion fixed in ice-
cold 4% phosphate-buffered paraformaldehyde for 3 h, and em-
bedded in paraffin. 5-
 
m
 
m thick sections from the brain and spinal
cord were prepared. The degree of demyelination and inflamma-
tion was assessed by luxol fast blue staining and nuclear fast red
counterstaining. All sections were examined using standard
bright-field optics and images were collected with a digitized
camera (3CCD PowerHAD; Sony).
 
Flow Cytometry.
 
Total spleen cells (10
 
6
 
) were stained with
each antibody for 20 min at 4
 
8
 
C in phosphate-buffered saline
containing 0.2% BSA, in 100 
 
m
 
l total volume. CD4-PE, CD44-
FITC, and CD45RB-FITC antibodies were all obtained from
BD PharMingen. 10,000 cells/sample were analyzed on a FACS-
Calibur™ (Becton Dickinson) using CELLQuest™ analysis soft-
ware (Becton Dickinson). Dead cells were excluded according to
forward and side scatter parameters.
 
Results
 
Abnormally Prolonged Myelin-directed T Cell Reactivity in
TNF
 
2
 
/
 
2
 
 Mice.
 
To examine whether TNF is involved in
the regression of autoimmune T cell responses, B6,129 and 
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B6,129.TNF
 
2
 
/
 
2
 
 mice were immunized with MBP in CFA
containing 50 
 
m
 
g H37Ra, and their responses were
monitored for 15 wk. Immunization of SJL.TNF
 
2
 
/
 
2
 
 and
SJL.H-2
 
b
 
 congenic mice with MBP in CFA containing 50 
 
m
 
g
H37Ra results in comparable T cell priming in both groups
of mice (9). Priming to MBP in B6,129 mice was, how-
ever, at least threefold lower than in SJL/J mice, with re-
producibly lower stimulation indices in B6,129.TNF
 
2
 
/
 
2
 
than in B6,129 mice 9 d after immunization (Fig. 1 a). De-
fective priming to MBP (with the protocol employed) in
B6,129.TNF
 
2
 
/
 
2
 
 mice, compared with B6,129 mice, was
due to reduced innate responsiveness of the former and
could be restored by supplementary H37Ra in the emul-
sion (our unpublished observation). Consistent with the
notion of spontaneous regression of primary myelin-spe-
cific T cell reactivity (5), virtually no “memory” was in-
duced in B6,129 mice, as spleen cells from these mice re-
sponded poorly or did not respond at all to MBP at later
time points (Fig. 1 a). Immunization with the control anti-
gen, OVA, confirmed that inability to elicit “memory” T
cell responses in B6,129 mice is a property of myelin-
derived but not of foreign antigens (data not shown), in
agreement with previous reports (5). Surprisingly, despite
defective MBP-specific T cell priming in B6,129.TNF
 
2
 
/
 
2
 
mice and in sharp contrast to B6,129 mice, MBP-specific T
cells accumulated in the spleen of B6,129.TNF
 
2
 
/
 
2
 
 mice
 
where strong proliferative responses to MBP were detected
49 d after immunization (Fig. 1 a). At 77 d after immuniza-
tion, MBP-specific T cell responses in B6,129.TNF
 
2
 
/
 
2
 
mice were considerably reduced but still detectable, com-
pared with B6,129 mice (Fig. 1 a). These results reveal that
regression or inactivation of the MBP-specific T cell re-
sponse in B6,129 mice is mediated, at least in part by TNF,
and that in the absence of TNF MBP-specific T cell
“memory” is induced.
 
Regression of Myelin-specific T Cell Responses Is Independent
of p55 TNFR Function.
 
Inactivation of autoimmune T
cells is thought to take place in splenic germinal centers
(20). To examine whether regression of autoimmunity by
TNF depends on the presence of the p55 TNFR and/or
correct splenic architecture, we employed p55 TNFR-
deficient mice, which like TNF
 
2
 
/
 
2
 
 mice (16) are also de-
fective in germinal center formation (21). MBP-immunized
B6,129.p55
 
2
 
/
 
2
 
 mice showed defective priming to MBP
(Fig. 1 b). Surprisingly, however, and in sharp contrast to
B6,129.TNF
 
2
 
/
 
2
 
 mice, MBP-specific T cell responses were
effectively controlled in B6,129.p55
 
2
 
/
 
2
 
 mice and were
similar to B6,129 mice 49 d after immunization (Fig. 1 b).
However, at 77 d after immunization, MBP-specific T cell
responses in B6,129.p55
 
2
 
/
 
2
 
 mice were overall low but
consistently higher than those in B6,129.TNF
 
2
 
/
 
2
 
 (Fig. 1
b). TNFR dependence of MBP-specific T cell regression
was confirmed in B6,129.p55p75
 
2
 
/
 
2
 
 mice, which, similarly
to B6,129.TNF
 
2
 
/
 
2
 
 mice, also failed to inactivate the MBP-
specific T cell response examined 49 d after immunization
(data not shown). Together, these findings show that
MBP-specific T cell inactivation by TNF is independent of
germinal center formation or the function p55 TNFR in
general, as it is not compromised in B6,129.p55
 
2
 
/
 
2
 
 mice.
 
Differential Termination of MBP-specific T Cell Responses in
p55
 
2
 
/
 
2
 
 Versus TNF
 
2
 
/
 
2
 
 Mice.
 
The p55 TNFR has been
implicated in the apoptotic removal of activated T cells
during the termination of T cell responses (3). Abnormally
prolonged MBP-specific T cell responses in the absence of
TNF could be indicative of defective T cell apoptosis.
However, after primary immunization, abnormally pro-
longed MBP-specific T cell reactivity is not observed in
B6,129.p55
 
2
 
/
 
2
 
 mice, and MBP-specific T cell responses
eventually decline even in B6,129.TNF
 
2
 
/
 
2
 
 mice. To ex-
amine the mechanism of termination of MBP reactivity in
the absence of TNF or the p55 TNFR, mice were immu-
nized with MBP in CFA and rechallenged with MBP in
IFA, 11–15 wk later, when the primary response to MBP
had subsided in all groups of mice (Fig. 1). We reasoned
that if termination of the MBP-specific T cell response in-
volved apoptotic removal of all activated MBP-specific T
cells, then we would not be able to detect a T cell response
to MBP after rechallenge. B6,129 mice showed strong
MBP-specific reactivity 5 d after rechallenge (Fig. 2), indi-
cating that antigen-specific T cells were not deleted in
wild-type mice and that they were inactivated by a differ-
ent mechanism, such as anergy or tolerance. B6,129.p55
 
2
 
/
 
2
 
and B6,129.p55p75
 
2
 
/
 
2
 
 mice exhibited significantly
increased MBP-specific T cell responses compared with
Figure 1. Abnormally prolonged T cell reactivity to MBP in
B6,129.TNF2/2 mice. T cell priming was examined in popliteal LN iso-
lated from B6,129.TNF2/2 and B6,129 (a) or B6,129.TNF2/2, B6,129,
and B6,129.p552/2 mice (b) 9 d after footpad immunization with 30 mg
MBP in CFA. MBP-specific “memory” responses were tested in the
spleen of B6,129.TNF2/2 and B6,129 (a) or B6,129.TNF2/2, B6,129,
and B6,129.p552/2 mice (b) 49 and 77 d after tail-base immunization
with MBP. Each curve represents the stimulation index (cpm of antigen-
stimulated cultures/cpm of cultures with medium alone) of two mice of
each genotype per time point pooled together. One representative set of
experiments (out of three performed) is shown. 
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B6,129 mice (Fig. 2), indicative of lack of T cell apoptosis
(note that T cell priming in mice lacking p55 TNFR sig-
naling is severely compromised; Fig. 1), in agreement with
the established function of the p55 TNFR (3). Similarly to
B6,129 mice, mechanisms other than apoptosis might con-
trol primary MBP reactivity in mice lacking the p55
TNFR because at this time point, the primary T cell re-
sponse is not readily detectable in these mice (Fig. 1), de-
spite lack of MBP-specific T cell apoptosis (Fig. 2). Surpris-
ingly, in contrast to all other groups of mice, rechallenge of
B6,129.TNF
 
2
 
/
 
2
 
 mice failed to induce any measurable T
cell response in the draining LN (Fig. 2). These data imply
a differential mechanism of termination of myelin-specific
T cell responses in the absence of TNF or the p55 TNFR,
and suggest a TNF-independent role for the p55 TNFR in
this process.
 
Sustained MBP Reactivity in TNF
 
2
 
/
 
2
 
 Mice Breaks Resis-
tance of H-2b Mice to MBP-induced EAE. Mice of the H-2b
haplotype are generally resistant to MBP-induced EAE. In
agreement to that, immunization of B6,129 mice with 30
mg MBP in CFA containing 100 mg H37Ra per mouse
without PTx coadministration failed to induce clinical or
histological evidence of EAE (Fig. 3, c and d, and Table I).
Surprisingly, however, starting from 4–5 wk after immuni-
zation almost half of B6,129.TNF2/2 mice exhibited clini-
cal evidence of EAE, which progressed into a chronic non-
remitting disease (10/23, maximal clinical score 2), whereas
B6,129 and B6,129.p552/2 remained healthy (data not
shown). Histological examination throughout the spinal
cords of MBP-immunized B6,129.TNF2/2 mice revealed
the presence of extensive inflammation and demyelination
(Fig. 3, a and b). Inflammation was evident histologically
even in B6,129.TNF2/2 and B6,129.p55p752/2 mice that
showed no clinical disease and affected a significant per-
centage of the immunized animals, whereas fewer mice ex-
hibited clear demyelination (Table I). In contrast, no histo-
logical evidence of inflammation or demyelination were
observed in B6,129 or B6,129.p552/2 mice (Table I).
These experiments indicate that inability to control or in-
activate an MBP-specific T cell response due to TNF (but
not p55 TNFR) deficiency effectively unmasks the resis-
tance of B6,129 mice to MBP-induced EAE.
TNF Protects MOG-susceptible Backgrounds against Chronic-
ity of MOG-induced EAE. To address the effect of TNF
deficiency on the autoimmune disease resulting from
MOG immunization of susceptible backgrounds, TNF2/2
mice were backcrossed to C57BL/6 mice for at least six
generations and EAE was induced by MOGp35–55 immu-
nization and PTx coadministration. In agreement with pre-
vious reports (7, 8), onset of clinical symptoms was delayed
by several days in B6.TNF2/2 mice compared with
C57BL/6 mice (Fig. 4 a). Surprisingly, however, despite
delayed onset and overall reduced disease, after recovery
from the acute episode of disease, B6.TNF2/2 mice devel-
oped a chronic-progressive form of EAE (Fig. 4 a), in con-
trast to C57BL/6 mice, which retained only a mild deficit
(Fig. 4 a). In separate experiments, EAE was induced by
MOGp35–55 immunization without PTx coadministra-
tion, a protocol that induces EAE only in C57BL/6 but
not in B6.TNF2/2 mice (see below, Fig. 7). Although
B6.TNF2/2 mice were not susceptible to the acute episode
of disease, they developed the late chronic-progressive
form, as seen in Fig. 4 a (data not shown). Similarly,
p55p752/2 mice on a MOG-resistant B6,129 background
Figure 2. Differential mechanism of
termination of MBP-specific T cell
responses in B6,129.p552/2 and
B6,129.p55p752/2 vs. B6,129.TNF2/2
mice. Mice were immunized in the tail-
base with MBP in CFA and 11–15 wk
later, MBP-specific T cell responses
were assayed in popliteal LN, isolated 5 d
after secondary footpad immunization
with MBP in IFA. Each curve repre-
sents the stimulation index of two mice
of each genotype pooled together. One
representative experiment of two per-
formed is shown.
Figure 3. Histological evidence of inflammation and demyelination in
MBP-immunized B6,129.TNF2/2 mice. B6,129.TNF2/2 (a and b) and
B6,129 mice (c and d) were immunized with MBP in CFA and tissues
were collected 9–15 wk later. Inflammation and demyelination were vi-
sualized by nuclear fast red and luxol fast blue staining, respectively. Ar-
rowhead in the top panel indicates inflammation; arrowheads in the bot-
tom panel indicate additionally demyelination; numbers within the
microphotographs indicate original magnification.
Table I. Histopathological Assessment of EAE in MBP-immunized 
B6,129 Mice
Genotype
Mean week
(range)
Inflammation
(%)
Demyelination
(%)
B6,129.TNF2/2 11.6 (9–15) 7/10 (70) 2/10 (20)
B6,129 11.7 (9–15) 0/8 (0) 0/8 (0)
B6,129.p552/2 11.3 (9–12) 0/9 (0) 0/9 (0)
B6,129.p55p752/2 12.5 (9–15) 2/6 (33) 1/6 (17)
Sections throughout the spinal cord of the immunized mice were
stained with luxol fast blue and nuclear fast red. The presence of
inflammation and demyelination was assayed qualitatively in 30–50
sections per mouse.431 Kassiotis and Kollias
(resistance conferred by the 129 genetic background [13]),
although fully refractory to the acute episode of EAE (Fig.
4 b), developed the late chronic-progressive form of EAE,
in contrast to B6,129 F2 control mice (Fig. 4 b). Together,
these experiments demonstrate that despite being beneficial
during the onset of disease, TNF deficiency is associated
with late complication of myelin-directed autoimmune dis-
ease.
Enhanced MOG-specific T Cell “Memory” Correlates with
Higher Numbers of Activated/Memory CD41 T Cells in
TNF2/2 Mice. To examine whether susceptibility to the
late chronic form of EAE in MOGp35-55–immunized
B6.TNF2/2 mice is associated with enhanced MOG reac-
tivity, “memory” T cell responses to MOGp35–55 were
measured 9–11 wk after EAE induction. Although spleen
cells from C57BL/6 mice retained a substantial degree of
MOG reactivity even after 11 wk after EAE induction,
MOGp35-55–specific T cell “memory” responses were
consistently higher in B6.TNF2/2 mice (Fig. 5 a), and this
was particularly evident in B6.TNF2/2 that did not receive
PTx (Fig. 5 b). To test whether enhanced MOG reacti-
vity in B6.TNF2/2 mice is related to uncontrolled ex-
pansion of MOGp35-55–specific T cells, the numbers of
CD44hiCD45RBlo CD41 T cells were quantified in the
spleens of B6.TNF2/2 and C57BL/6 mice 9–11 wk after
EAE induction (Fig. 6). Notably, CD44hiCD45RBlo
CD41 T cell numbers were elevated in nonimmunized
B6.TNF2/2 mice compared with control C57BL/6 mice
(Fig. 6). More importantly, the numbers of CD44hi
CD45RBlo CD41 T cells were considerably increased in
MOGp35-55–immunized B6.TNF2/2 mice, but more ev-
idently without PTx coadministration (Fig. 6). In contrast,
CD44hiCD45RBlo CD41 T cell numbers were constant or
even reduced in MOGp35-55–immunized C57BL/6 mice
(Fig. 6). Elevated CD44hiCD45RBlo CD41 T cell num-
bers were observed also in the spleens of MOGp35-55–
Figure 4. B6.TNF2/2 and B6,129.p55p752/2 mice develop a late,
chronic form of EAE after immunization with MOGp35–55. EAE was
induced in mice by MOGp35–55 immunization in CFA containing 1 mg
H37Ra per mouse. On the day of immunization and 48 h later, (a) 400
ng PTx (in the case of B6.TNF2/2 and C57BL/6 mice) or (b) 200 ng
PTx (in the case of B6,129.p55p752/2 and B6,129 F2 mice) were coad-
ministered intraperitoneally. Each curve represents the mean clinical
score  6 SD of each group. Note that intervals in the first or the acute phase
are in alternate days, whereas the second or chronic phase are in weeks.
Figure 5. Enhanced MOGp35-55–specific T cell responses in
B6.TNF2/2 9–11 wk after immunization. EAE was induced in
B6.TNF2/2 and C57BL/6 mice by MOGp35–55 immunization with (a)
or without PTx coadministration (b), and T cell responses to MOGp35–
55 were tested in total spleen cells 9–11 wk later. Each curve represents
the stimulation index of two to five mice of each genotype pooled to-
gether. One representative experiment of three performed is shown.
Figure 6. Elevated numbers of CD44hiCD45RBlo CD41 T cells in
B6.TNF2/2 mice. EAE was induced in B6.TNF2/2 and C57BL/6 mice
by MOGp35–55 immunization with or without PTx coadministration,
and CD44 and CD45RB phenotypes of CD41 T cell were analyzed and
compared with age-matched nonimmunized mice 9–11 wk later by
flow cytometry. Each plot depicts CD4, CD44, and CD45RB pheno-
types in total spleen cells pooled from four to five mice. Numbers
underneath the regions represent the percentage of CD44hi or
CD45RBloCD41 T cells, expressed as percentage of total CD41 T cells.
The percentage of total CD41 T cells in the spleens of the different
groups did not vary significantly.432 Suppression of T Cell Autoimmunity by Tumor Necrosis Factor
immunized B6,129.p55p752/2 mice (42% CD44hi, 54%
CD45RBlo in B6,129.p55p752/2 mice versus 25% CD44hi,
44% CD45RBlo in B6,129 mice, of total CD41 T cells at
18 wk after EAE induction). These data indicate that TNF
influences the expansion or survival of activated/memory
T cells.
Resistance to Reinduction of EAE Depends on TNF but Not
on the p55 TNFR. Mice that have recovered from an
acute episode of EAE are normally resistant to reinduction
of the disease. To examine whether failure of B6.TNF2/2
mice to control MOGp35-55–specific T cell responses is
linked to inability to establish tolerance to MOGp35–55
and resistance to reinduction of disease, EAE was rein-
duced in mice 50 d after primary EAE induction. More-
over, to verify that the resulting disease after reinduction of
EAE in B6.TNF2/2 mice is due to enhanced MOGp35-
55–specific T cell responses, we used a low dose of PTx, in
light of the fact that TNF2/2 mice, in contrast to control
mice, are totally refractory to EAE induction if PTx is re-
duced or omitted (unpublished observations). Indeed, the
EAE induction protocol employed induced the acute epi-
sode of EAE only in C57BL/6 but not in B6.TNF2/2 or
B6.p552/2 mice (Fig. 7). As expected, C57BL/6 mice re-
covered from the acute EAE and were totally refractory to
reinduction of EAE (Fig. 7). In contrast, B6.TNF2/2 mice
were resistant to the initial episode of EAE but readily de-
veloped the disease after reinduction (Fig. 7). More impor-
tantly, B6.p552/2 mice, which were also resistant to the
initial episode of EAE, were tolerant to EAE reinduction
(Fig. 7). Thus, TNF but not the p55 TNFR is required for
the induction of tolerance to the immunizing self-antigen
and the establishment of resistance to EAE.
Discussion
Data presented in this study suggest that TNF plays at
least two distinct roles during the progression of autoim-
mune encephalomyelitis. In agreement with previous re-
ports (8, 9, 15), TNF appears to exert acute detrimental
activities after initiation of a myelin-directed immune re-
sponse. Interestingly, however, TNF appears to be addi-
tionally required for the spontaneous regression of this re-
activity and for the subsequent remission of the clinical
syndrome. In the absence of TNF, myelin-specific T cells
that would otherwise be inactivated accumulate in the
spleen of the immunized animals and a late chronic form of
EAE develops. Our results demonstrate that TNF is essen-
tial in downregulating or inactivating a potentially detri-
mental autoimmune T cell response against myelin anti-
gens, and that it can therefore protect against chronic EAE.
This notion adds an extra level of complexity with respect
to the role of TNF in MS pathogenesis. High TNF levels
will ensure efficient inactivation of any potentially detri-
mental myelin-specific T cell response but will facilitate
disease progression by accelerating onset of lesions and
contributing to CNS demyelination. Conversely, low TNF
levels will delay the onset of lesions and reduce the extent
of CNS demyelination but will enable the mounting of an
extremely unfavorable myelin-specific T cell response.
These two extremes of many intermediate possible scenar-
ios indicate that fine-tuning and precise control of TNF
levels or function are required to minimize the risk of au-
toimmune disease development. A similar defect in sup-
pressing the expansion of activated myelin-specific T cells,
also leading to exacerbation of EAE, has recently been de-
scribed in IFN-g2/2 mice (22). However, exacerbation of
EAE in IFN-g2/2 mice appears to involve only the acute
phase of the disease. Therefore, in contrast to IFN-g,
which shows early antiinflammatory properties, TNF is
clearly proinflammatory during the acute phase of EAE, as
well as dominantly immunosuppressive (and thus “antiin-
flammatory”) during the consequent phases of the disease.
This model is consistent with the immune activating and
disease enhancing activities of anti-TNF treatment recently
evidenced in MS patients (12, 13).
The precise mechanism by which TNF mediates regres-
sion of myelin-specific T cell responses is not yet clear.
Both TNF receptors have been implicated in antigen-
induced T cell apoptosis (2, 23). However, prolonged pri-
mary myelin reactivity and late onset EAE were not ob-
served in p552/2 mice, indicating that defective p55
TNFR-mediated apoptosis cannot fully account for this
phenomenon, and that the p75 TNFR may be sufficient to
mediate apoptotic removal of activated T cells. Alterna-
tively, TNF/p75 TNFR signals may influence the long-
term survival or expansion of pathogenic activated/memory
T cells through mechanisms other than apoptosis. Pre-
liminary data with mice lacking the p75 TNFR suggested
that although the p75 TNFR is sufficient to control myelin
reactivity, it is not essential, as p752/2 mice, similarly to
p552/2 mice, failed to develop the late autoimmune com-
plications seen in TNF2/2 or p55p752/2 mice. However,
it remains unclear whether the same or an entirely different
mechanism is responsible for the control of myelin reactiv-
ity in p552/2 and p752/2 mice, respectively. An additional
Figure 7. Establishment of resistance to MOG-induced EAE in
B6.p552/2 and C57BL/6 mice but not in B6.TNF2/2 after MOGp35–55
immunization. EAE was induced in mice by MOGp35–55 immunization
in CFA containing 1 mg H37Ra per mouse. On the day of immunization
and 48 h later, mice received 200 ng PTx intraperitoneally. 50 d later,
EAE was reinduced using the same protocol. Each curve represents the
mean clinical score 6 SD of each group.433 Kassiotis and Kollias
line of evidence against a role for p55-mediated T cell ap-
optosis in the control of autoimmune T cells by TNF may
be the fact that lack of p55-mediated T cell removal, re-
flected by enhanced responses to secondary challenge in
p552/2 and p55p752/2 mice, is not observed in TNF2/2
mice, implying a TNF-independent role for the p55
TNFR in this process. Indeed, p55 TNFR triggering by
ligands other than TNF, such as lymphotoxin (LT)-a, is
also possible, given the potent T cell cytotoxic effect of
LT-a (24). If p55-mediated T cell apoptotic pathways are
largely unaffected in mice lacking TNF, it is conceivable
that instead of, or in addition to, increasing the frequency
of myelin-specific T cells, TNF deficiency allows autoim-
mune T cells to reach a disease-causing threshold of activa-
tion. Inactivation of autoimmune T cells by TNF could
also explain the immune or disease suppressive effect of
TNF in other organ specific (25, 26) or systemic autoim-
mune diseases (27, 28). However, it remains to be estab-
lished whether a universal mechanism of suppression is em-
ployed in all cases.
Understanding the molecular and cellular mechanisms
underlying the proinflammatory and immunosuppressive
functions of TNF should allow more effective design of
therapeutic approaches. The fact that the inactivation of
myelin-specific autoimmunity by TNF displays different re-
quirements for the p55 TNFR than the initiation of EAE
becomes crucially important for immune modulation. An
immunosuppressive role with clinical relevance for TNF is
also supported by the systemic autoimmunity frequently as-
sociated with TNF blockade in human patients (29, 30). In-
terestingly, recent data suggest that systemic autoimmunity
develops spontaneously in TNF2/2 but not in p552/2 mice
(31). Together, these results indicate that by specifically
blocking the function of the p55 TNFR, it may be possible
to inhibit the detrimental proinflammatory or cytotoxic
contributions of TNF in demyelinating disease while re-
taining its beneficial involvement in the inactivation of the
autoimmune response. The paradigm set in this study for
autoimmune demyelination may also apply in a broad range
of chronic inflammatory/autoimmune diseases, and may
prove useful in the future design of rational therapies.
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